Skip to main content

Interactions between Danazol and Ergonovine

1 drug interaction and 23 additional warnings found for the following 2 drugs:

Add/remove drugs

Drug interactions

Moderate drug interactions

Moderate:

danazol ergonovine

Applies to: danazol and ergonovine
Monitor

Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of ergot derivatives, which are primarily metabolized by the isoenzyme. The interaction has occurred in patients receiving ergotamine or dihydroergotamine with potent CYP450 3A4 inhibitors such as macrolide antibiotics and protease inhibitors. Clinical ergotism has been reported, which can lead to gangrene and myocardial infarction in severe cases. Even small, single doses of ergotamine have resulted in clinically significant interactions, occasionally resulting in surgical amputation or death. No data are available for other, less potent CYP450 3A4 inhibitors.

Management

Caution is advised during concomitant use of ergot derivatives with mild or moderate CYP450 3A4 inhibitors. Patients should be monitored for potential ergot toxicity including peripheral vasospasm, ischemia, thrombosis, tachycardia, and hypertension.

References (25)
  1. Leroy F, Asseman P, Pruvost P, Adnet P, Lacroix D, Thery C (1988) "Dihydroergotamine-erythromycin-induced ergotism." Ann Intern Med, 109, p. 249
  2. Matthews NT, Havill JH (1979) "Ergotism with therapeutic doses of ergotamine tartrate." N Z Med J, 89, p. 476-7
  3. Francis H, Tyndall A, Webb J (1984) "Severe vascular spasm due to erythromycin-ergotamine interaction." Clin Rheumatol, 3, p. 243-6
  4. Hayton AC (1969) "Precipitation of acute ergotism by triacetyloleandomycin." N Z Med J, 69, p. 42
  5. (2002) "Product Information. D.H.E. 45 (dihydroergotamine)." Sandoz Pharmaceuticals Corporation
  6. Ghali R, De Lean J, Douville Y, Noel HP, Labbe R (1993) "Erythromycin-associated ergotamine intoxication: arteriographic and electrophysiologic analysis of a rare cause of severe ischemia of the lower extremities and associated ischemic neuropathy." Ann Vasc Surg, 7, p. 291-6
  7. Horowitz RS, Dart RC, Gomez HF (1996) "Clinical ergotism with lingual ischemia induced by clarithromycin-ergotamine interaction." Arch Intern Med, 156, p. 456-8
  8. (2001) "Product Information. Migranal (dihydroergotamine nasal)." Novartis Pharmaceuticals
  9. Rosenthal E, Sala F, Chichmanian RM, Batt M, Cassuto JP (1999) "Ergotism related to concurrent administration of ergotamine tartrate and indinavir." JAMA, 281, p. 987
  10. Liaudet L, Buclin T, Jaccard C, Eckert P (1999) "Severe ergotism associated with interaction between ritonavir and ergotamine." Br Med J, 318, p. 771
  11. Caballero-Granado FJ, Viciana P, Cordero E, Gomez-Vera MJ, del Nozal M, Lopez-Cortes LF (1997) "Ergotism related to concurrent administration of ergotamine tartrate and ritonavir in an AIDS patient." Antimicrob Agents Chemother, 41, p. 1207
  12. Dresser GK, Spence JD, Bailey DG (2000) "Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition." Clin Pharmacokinet, 38, p. 41-57
  13. Bird PA, Sturgess AD (2000) "Clinical ergotism with severe bilateral upper limb ischaemia precipitated by an erythromycin - ergotamine drug interaction." Aust N Z J Med, 30, p. 635-6
  14. Eadie MJ (2001) "Clinically significant drug interactions with agents specific for migraine attacks." Cns Drugs, 15, p. 105-18
  15. Spiegel M, Schmidauer C, Kampfl A, Sarcletti M, Poewe W (2001) "Cerebral ergotism under treatment with ergotamine and ritonavir." Neurology, 57, p. 743-4
  16. Vila A, Mykietiuk A, Bonvehi P, Temporiti E, Uruena A, Herrera F (2001) "Clinical ergotism induced by ritonavir." Scand J Infect Dis, 33, p. 788-9
  17. Montero A, Giovannoni AG, Tvrde PL (1999) "Leg ischemia in a patient receiving ritonavir and ergotamine." Ann Intern Med, 130, p. 329
  18. Liaudet L (1999) "Severe ergotism associated with interaction between ritonavir and ergotamine." BMJ, 318, p. 771
  19. Mortier E, Pouchet J, Vinceneux P, Lalande M (2001) "Ergotism related to interaction between nelfinavir and ergotamine." Am J Med, 110, p. 594
  20. Blanche P, Rigolet A, Gombert B, Ginsburg C, Salmon D, Sicard D (1999) "Ergotism related to a single dose of ergotamine tartrate in an AIDS patient treated with ritonavir." Postgrad Med J, 75, p. 546-7
  21. Ausband SC, Goodman PE (2001) "An unusual case of clarithromycin associated ergotism." J Emerg Med, 4, p. 411-3
  22. Baldwin ZK, Ceraldi CC (2003) "Ergotism associated with HIV antiviral protease inhibitor therapy." J Vasc Surg, 37, p. 676-8
  23. Tribble MA, Gregg CR, Margolis DM, Amirkhan R, Smith JW (2002) "Fatal ergotism induced by an HIV protease inhibitor." Headache, 42, p. 694-5
  24. (2004) "Product Information. Cafergot (caffeine-ergotamine)." Novartis Pharmaceuticals
  25. Srisuma S, Lavonas EJ, Wananukul W (2014) "Ergotism and factitious hypotension associated with interaction of ergotamine with CYP3A4 inhibitors." Clin Toxicol (Phila), p. 1-4

Food/lifestyle interactions

Moderate food/lifestyle interactions

Moderate:

ergonovine Food/Lifestyle

Applies to: ergonovine
Monitor

Grapefruit or grapefruit juice may increase the plasma concentrations of orally administered drugs that are substrates of the CYP450 3A4 isoenzyme. The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit. Because grapefruit juice inhibits primarily intestinal rather than hepatic CYP450 3A4, the magnitude of interaction is greatest for those drugs that undergo significant presystemic metabolism by CYP450 3A4 (i.e., drugs with low oral bioavailability). In general, the effect of grapefruit juice is concentration-, dose- and preparation-dependent, and can vary widely among brands. Certain preparations of grapefruit juice (e.g., high dose, double strength) have sometimes demonstrated potent inhibition of CYP450 3A4, while other preparations (e.g., low dose, single strength) have typically demonstrated moderate inhibition. Pharmacokinetic interactions involving grapefruit juice are also subject to a high degree of interpatient variability, thus the extent to which a given patient may be affected is difficult to predict.

Management

Patients who regularly consume grapefruit or grapefruit juice should be monitored for adverse effects and altered plasma concentrations of drugs that undergo significant presystemic metabolism by CYP450 3A4. Grapefruit and grapefruit juice should be avoided if an interaction is suspected. Orange juice is not expected to interact with these drugs.

References (32)
  1. Edgar B, Bailey D, Bergstrand R, et al. (1992) "Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance." Eur J Clin Pharmacol, 42, p. 313-7
  2. Jonkman JH, Sollie FA, Sauter R, Steinijans VW (1991) "The influence of caffeine on the steady-state pharmacokinetics of theophylline." Clin Pharmacol Ther, 49, p. 248-55
  3. Bailey DG, Arnold JM, Munoz C, Spence JD (1993) "Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin." Clin Pharmacol Ther, 53, p. 637-42
  4. Bailey DG, Arnold JMO, Spence JD (1994) "Grapefruit juice and drugs - how significant is the interaction." Clin Pharmacokinet, 26, p. 91-8
  5. Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A (1994) "Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation." Pharmazie, 49, p. 522-4
  6. Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD (1993) "Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics." Clin Pharmacol Ther, 54, p. 589-94
  7. Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG (1995) "Drug-food interactions in clinical practice." J Fam Pract, 40, p. 376-84
  8. (1995) "Grapefruit juice interactions with drugs." Med Lett Drugs Ther, 37, p. 73-4
  9. Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ (1995) "Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice." Clin Pharmacol Ther, 58, p. 127-31
  10. Min DI, Ku YM, Geraets DR, Lee HC (1996) "Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers." J Clin Pharmacol, 36, p. 469-76
  11. Majeed A, Kareem A (1996) "Effect of grapefruit juice on cyclosporine pharmacokinetics." Pediatr Nephrol, 10, p. 395
  12. Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS (1996) "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol, 42, p662
  13. Josefsson M, Zackrisson AL, Ahlner J (1996) "Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers." Eur J Clin Pharmacol, 51, p. 189-93
  14. Kantola T, Kivisto KT, Neuvonen PJ (1998) "Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid." Clin Pharmacol Ther, 63, p. 397-402
  15. Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A (1998) "Interaction between grapefruit juice and diazepam in humans." Eur J Drug Metab Pharmacokinet, 23, p. 55-9
  16. Bailey DG, Malcolm J, Arnold O, Spence JD (1998) "Grapefruit juice-drug interactions." Br J Clin Pharmacol, 46, p. 101-10
  17. Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR (1998) "Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans." Clin Pharmacol Ther, 64, p. 248-56
  18. Garg SK, Kumar N, Bhargava VK, Prabhakar SK (1998) "Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy." Clin Pharmacol Ther, 64, p. 286-8
  19. Lilja JJ, Kivisto KT, Neuvonen PJ (1998) "Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors." Clin Pharmacol Ther, 64, p. 477-83
  20. Fuhr U, Maier-Bruggemann A, Blume H, et al. (1998) "Grapefruit juice increases oral nimodipine bioavailability." Int J Clin Pharmacol Ther, 36, p. 126-32
  21. Lilja JJ, Kivisto KT, Neuvonen PJ (1999) "Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin." Clin Pharmacol Ther, 66, p. 118-27
  22. Eagling VA, Profit L, Back DJ (1999) "Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components." Br J Clin Pharmacol, 48, p. 543-52
  23. Damkier P, Hansen LL, Brosen K (1999) "Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine." Br J Clin Pharmacol, 48, p. 829-38
  24. Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC (1999) "The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study." Clin Ther, 21, p. 1890-9
  25. Dresser GK, Spence JD, Bailey DG (2000) "Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition." Clin Pharmacokinet, 38, p. 41-57
  26. Gunston GD, Mehta U (2000) "Potentially serious drug interactions with grapefruit juice." S Afr Med J, 90, p. 41
  27. Takanaga H, Ohnishi A, Maatsuo H, et al. (2000) "Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model." Br J Clin Pharmacol, 49, p. 49-58
  28. Libersa CC, Brique SA, Motte KB, et al. (2000) "Dramatic inhibition of amiodarone metabolism induced by grapefruit juice." Br J Clin Pharmacol, 49, p. 373-8
  29. Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR (2000) "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther, 68, p. 468-77
  30. Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E (2001) "Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers." Ther Drug Monit, 23, p. 369-73
  31. Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K (1993) "Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects." Eur J Clin Pharmacol, 44, p. 295-8
  32. Flanagan D (2005) "Understanding the grapefruit-drug interaction." Gen Dent, 53, 282-5; quiz 286

Disease interactions

22 potential interactions Applies to: 19 conditions, including High Blood Pressure, Migraine, Heart Failure, Seizures, and Abnormal Uterine Bleeding.

Abnormal Uterine Bleeding

Major:

danazol

Danazol has a major potential interaction with Abnormal Uterine Bleeding.

The use of danazol is contraindicated in patients with undiagnosed, abnormal genital bleeding. Patients should be evaluated to ensure that neoplastic lesions are not present. Alterations of menstruation including irregular cycles, amenorrhea, breakthrough bleeding, and spotting have occurred during danazol therapy.

Arteriovenous Shunting

Major:

ergonovine

Ergonovine has a major potential interaction with Arteriovenous Shunting.

The amine ergot alkaloids, ergonovine and methylergonovine, can cause serious cardiovascular complications because of their vasospastic effects. Hypertension (more often with ergonovine) has been most commonly reported, particularly when administered IV undiluted or at an excessive rate or when used in conjunction with regional anesthesia or vasoconstrictors. Headaches, seizures, cerebrovascular accidents and death have been associated with the hypertensive episodes. Other, less common adverse effects include acute myocardial infarction, transient chest pains, thrombophlebitis, tachycardia and palpitations. Therapy with ergot alkaloids should generally be avoided, except under special circumstances, in patients with chronic hypertension, preeclampsia or eclampsia, cardiovascular disease, cerebrovascular disease, or peripheral vascular disease. Caution is advised when these agents are administered to patients with venoatrial shunts, mitral valve stenosis, or sepsis. Close monitoring of cardiovascular status is highly recommended during therapy.

Bleeding Disorder

Major:

danazol

Danazol has a major potential interaction with Bleeding Disorder.

Danazol is contraindicated in patients with thrombosis or thromboembolic disease or a history of such events. Thromboembolism, thrombotic and thrombophlebitic events, including fatal strokes, have occurred during danazol therapy. Hematuria, menstrual spotting and thrombocytopenia have also occurred. Additionally, therapy with danazol should be administered cautiously in patients with or predisposed to bleeding/clotting disorders.

Cardiovascular Conditions and Disorders

Major:

ergonovine

Ergonovine has a major potential interaction with Cardiovascular Conditions and Disorders.

The amine ergot alkaloids, ergonovine and methylergonovine, can cause serious cardiovascular complications because of their vasospastic effects. Hypertension (more often with ergonovine) has been most commonly reported, particularly when administered IV undiluted or at an excessive rate or when used in conjunction with regional anesthesia or vasoconstrictors. Headaches, seizures, cerebrovascular accidents and death have been associated with the hypertensive episodes. Other, less common adverse effects include acute myocardial infarction, transient chest pains, thrombophlebitis, tachycardia and palpitations. Therapy with ergot alkaloids should generally be avoided, except under special circumstances, in patients with chronic hypertension, preeclampsia or eclampsia, cardiovascular disease, cerebrovascular disease, or peripheral vascular disease. Caution is advised when these agents are administered to patients with venoatrial shunts, mitral valve stenosis, or sepsis. Close monitoring of cardiovascular status is highly recommended during therapy.

Diabetes Mellitus

Major:

danazol

Danazol has a major potential interaction with Diabetes Mellitus.

Danazol possess androgenic activity that can result in salt and water retention. Danazol is eliminated by the kidney, and its use is contraindicated in patients with severe renal dysfunction. It should also be administered cautiously in patients adversely affected by volume overload, such as patients suffering from epilepsy, diabetes mellitus, migraine, cardiac or renal dysfunction, polycythemia and hypertension. These patients will require careful observation.

Fluid Retention

Major:

danazol

Danazol has a major potential interaction with Fluid Retention.

Danazol possess androgenic activity that can result in salt and water retention. Danazol is eliminated by the kidney, and its use is contraindicated in patients with severe renal dysfunction. It should also be administered cautiously in patients adversely affected by volume overload, such as patients suffering from epilepsy, diabetes mellitus, migraine, cardiac or renal dysfunction, polycythemia and hypertension. These patients will require careful observation.

Heart Disease

Major:

danazol

Danazol has a major potential interaction with Heart Disease.

Danazol is contraindicated in patients with marked impaired cardiac function.

Heart Failure

Major:

danazol

Danazol has a major potential interaction with Heart Failure.

Danazol possess androgenic activity that can result in salt and water retention. Danazol is eliminated by the kidney, and its use is contraindicated in patients with severe renal dysfunction. It should also be administered cautiously in patients adversely affected by volume overload, such as patients suffering from epilepsy, diabetes mellitus, migraine, cardiac or renal dysfunction, polycythemia and hypertension. These patients will require careful observation.

High Blood Pressure

Major:

danazol

Danazol has a major potential interaction with High Blood Pressure.

Danazol possess androgenic activity that can result in salt and water retention. Danazol is eliminated by the kidney, and its use is contraindicated in patients with severe renal dysfunction. It should also be administered cautiously in patients adversely affected by volume overload, such as patients suffering from epilepsy, diabetes mellitus, migraine, cardiac or renal dysfunction, polycythemia and hypertension. These patients will require careful observation.

Major:

ergonovine

Ergonovine has a major potential interaction with High Blood Pressure.

The use of the amine ergot alkaloids, ergonovine and methylergonovine, is considered by some clinicians to be contraindicated in patients with hypertension. These agents can cause hypertension, particularly when administered IV undiluted or at an excessive rate or when used in conjunction with regional anesthesia or vasoconstrictors. Headaches, seizures, cerebrovascular accidents and death have been associated with the hypertensive episodes. Patients with chronic hypertension or preeclampsia may be at increased risk for these complications. Of the two agents, methylergonovine has less tendency to cause hypertension, although preferably neither agent should be administered to at- risk patients.

History, Thrombotic/Thromboembolic Disorder

Major:

danazol

Danazol has a major potential interaction with History, Thrombotic/Thromboembolic Disorder.

Danazol is contraindicated in patients with thrombosis or thromboembolic disease or a history of such events. Thromboembolism, thrombotic and thrombophlebitic events, including fatal strokes, have occurred during danazol therapy. Hematuria, menstrual spotting and thrombocytopenia have also occurred. Additionally, therapy with danazol should be administered cautiously in patients with or predisposed to bleeding/clotting disorders.

Liver Disease

Major:

danazol

Danazol has a major potential interaction with Liver Disease.

The use of danazol is contraindicated in patients with severe hepatic impairment. Danazol is metabolized by the liver to inactive forms. Metabolic and therapeutic activity of danazol may be altered in patients with severe hepatic dysfunction. Elevated serum transaminase levels, peliosis hepatis and benign hepatic adenoma have occurred during chronic administration of danazol. Therapy with danazol should be administered cautiously in patients with or predisposed to hepatic dysfunction.

Moderate:

ergonovine

Ergonovine has a moderate potential interaction with Liver Disease.

The amine ergot alkaloids, ergonovine and methylergonovine, appear to be eliminated by both renal and hepatic routes. Patients with renal and/or liver disease may be at greater risk for adverse effects from these agents due to decreased drug clearance. Caution is advised if these agents are used. Dosage adjustments may be necessary.

Migraine

Major:

danazol

Danazol has a major potential interaction with Migraine.

Danazol possess androgenic activity that can result in salt and water retention. Danazol is eliminated by the kidney, and its use is contraindicated in patients with severe renal dysfunction. It should also be administered cautiously in patients adversely affected by volume overload, such as patients suffering from epilepsy, diabetes mellitus, migraine, cardiac or renal dysfunction, polycythemia and hypertension. These patients will require careful observation.

Porphyria

Major:

danazol

Danazol has a major potential interaction with Porphyria.

The use of danazol is contraindicated in patients with porphyria. Danazol can induce production of delta- aminolevulinic acid (ALA) synthetase activity resulting in porphyrin metabolism.

Prostate Tumor, Benign

Major:

danazol

Danazol has a major potential interaction with Prostate Tumor, Benign.

The use of danazol is contraindicated in patients with androgen- dependent tumors.

Pseudotumor Cerebri

Major:

danazol

Danazol has a major potential interaction with Pseudotumor Cerebri.

Intracranial hypertension (pseudotumor cerebri) has occurred in patients receiving danazol. Therapy with danazol should be administered cautiously in patients with or predisposed to cerebral or papilledema and/or intracranial hypertension.

Renal Dysfunction

Major:

danazol

Danazol has a major potential interaction with Renal Dysfunction.

Danazol possess androgenic activity that can result in salt and water retention. Danazol is eliminated by the kidney, and its use is contraindicated in patients with severe renal dysfunction. It should also be administered cautiously in patients adversely affected by volume overload, such as patients suffering from epilepsy, diabetes mellitus, migraine, cardiac or renal dysfunction, polycythemia and hypertension. These patients will require careful observation.

Moderate:

ergonovine

Ergonovine has a moderate potential interaction with Renal Dysfunction.

The amine ergot alkaloids, ergonovine and methylergonovine, appear to be eliminated by both renal and hepatic routes. Patients with renal and/or liver disease may be at greater risk for adverse effects from these agents due to decreased drug clearance. Caution is advised if these agents are used. Dosage adjustments may be necessary.

Seizures

Major:

danazol

Danazol has a major potential interaction with Seizures.

Danazol possess androgenic activity that can result in salt and water retention. Danazol is eliminated by the kidney, and its use is contraindicated in patients with severe renal dysfunction. It should also be administered cautiously in patients adversely affected by volume overload, such as patients suffering from epilepsy, diabetes mellitus, migraine, cardiac or renal dysfunction, polycythemia and hypertension. These patients will require careful observation.

Tachyarrhythmia

Major:

ergonovine

Ergonovine has a major potential interaction with Tachyarrhythmia.

The amine ergot alkaloids, ergonovine and methylergonovine, can cause serious cardiovascular complications because of their vasospastic effects. Hypertension (more often with ergonovine) has been most commonly reported, particularly when administered IV undiluted or at an excessive rate or when used in conjunction with regional anesthesia or vasoconstrictors. Headaches, seizures, cerebrovascular accidents and death have been associated with the hypertensive episodes. Other, less common adverse effects include acute myocardial infarction, transient chest pains, thrombophlebitis, tachycardia and palpitations. Therapy with ergot alkaloids should generally be avoided, except under special circumstances, in patients with chronic hypertension, preeclampsia or eclampsia, cardiovascular disease, cerebrovascular disease, or peripheral vascular disease. Caution is advised when these agents are administered to patients with venoatrial shunts, mitral valve stenosis, or sepsis. Close monitoring of cardiovascular status is highly recommended during therapy.

Thrombotic/Thromboembolic Disorder

Major:

danazol

Danazol has a major potential interaction with Thrombotic/Thromboembolic Disorder.

Danazol is contraindicated in patients with thrombosis or thromboembolic disease or a history of such events. Thromboembolism, thrombotic and thrombophlebitic events, including fatal strokes, have occurred during danazol therapy. Hematuria, menstrual spotting and thrombocytopenia have also occurred. Additionally, therapy with danazol should be administered cautiously in patients with or predisposed to bleeding/clotting disorders.

Report options

Loading...
QR code containing a link to this page

More resources

danazol

A total of 270 drugs are known to interact with danazol.

ergonovine

A total of 284 drugs are known to interact with ergonovine.

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer